These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25488402)

  • 21. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.
    Rose RB; Craik CS; Stroud RM
    Biochemistry; 1998 Feb; 37(8):2607-21. PubMed ID: 9485411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptability and flexibility of HIV-1 protease.
    Kumar M; Hosur MV
    Eur J Biochem; 2003 Mar; 270(6):1231-9. PubMed ID: 12631281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamic flaps in HIV-1 protease adopt unique ordering at different stages in the catalytic cycle.
    Karthik S; Senapati S
    Proteins; 2011 Jun; 79(6):1830-40. PubMed ID: 21465560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding to the open conformation of HIV-1 protease.
    Lexa KW; Carlson HA
    Proteins; 2011 Jul; 79(7):2282-90. PubMed ID: 21604303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Studies of a Rationally Selected Multi-Drug Resistant HIV-1 Protease Reveal Synergistic Effect of Distal Mutations on Flap Dynamics.
    Agniswamy J; Louis JM; Roche J; Harrison RW; Weber IT
    PLoS One; 2016; 11(12):e0168616. PubMed ID: 27992544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug pressure selected mutations in HIV-1 protease alter flap conformations.
    Galiano L; Ding F; Veloro AM; Blackburn ME; Simmerling C; Fanucci GE
    J Am Chem Soc; 2009 Jan; 131(2):430-1. PubMed ID: 19140783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
    C S V; Tamizhselvi R; Munusami P
    J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Solvation influences flap collapse in HIV-1 protease.
    Meagher KL; Carlson HA
    Proteins; 2005 Jan; 58(1):119-25. PubMed ID: 15521062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms--structure/function relationship and influence of crystal packing.
    Lange-Savage G; Berchtold H; Liesum A; Budt KH; Peyman A; Knolle J; Sedlacek J; Fabry M; Hilgenfeld R
    Eur J Biochem; 1997 Sep; 248(2):313-22. PubMed ID: 9346283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function.
    Ishima R; Freedberg DI; Wang YX; Louis JM; Torchia DA
    Structure; 1999 Sep; 7(9):1047-55. PubMed ID: 10508781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.
    Appadurai R; Senapati S
    Biochemistry; 2017 Jun; 56(23):2907-2920. PubMed ID: 28505418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
    Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
    FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope.
    Ozen A; Haliloğlu T; Schiffer CA
    J Mol Biol; 2011 Jul; 410(4):726-44. PubMed ID: 21762811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
    Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
    J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: a structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations.
    Kurt N; Scott WR; Schiffer CA; Haliloglu T
    Proteins; 2003 May; 51(3):409-22. PubMed ID: 12696052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular dynamics and ligand docking of a hinge region variant of South African HIV-1 subtype C protease.
    Zondagh J; Balakrishnan V; Achilonu I; Dirr HW; Sayed Y
    J Mol Graph Model; 2018 Jun; 82():1-11. PubMed ID: 29625416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
    Meher BR; Wang Y
    J Phys Chem B; 2012 Feb; 116(6):1884-900. PubMed ID: 22239286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
    Seibold SA; Cukier RI
    Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
    Clemente JC; Moose RE; Hemrajani R; Whitford LR; Govindasamy L; Reutzel R; McKenna R; Agbandje-McKenna M; Goodenow MM; Dunn BM
    Biochemistry; 2004 Sep; 43(38):12141-51. PubMed ID: 15379553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validating solution ensembles from molecular dynamics simulation by wide-angle X-ray scattering data.
    Chen PC; Hub JS
    Biophys J; 2014 Jul; 107(2):435-447. PubMed ID: 25028885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.